How Health Economists Calculate the Value of a Year of Life Using the QALY Metric

When a government agency evaluates a new highway, it measures the cost of concrete against the projected hours of commuter time saved. When a national health system evaluates a new medical treatment, the calculation is fundamentally the same, with one critical difference: the currency being measured is human health, quantified down to the decimal point. This measurement relies on the Quality-Adjusted Life Year, or QALY, a metric that attempts to solve one of the most difficult problems in public health: how to rationally allocate a finite budget across an infinite demand for medical care.[1][2]

The QALY operates on a deceptively simple premise. It combines the length of life and the quality of life into a single index number. One QALY represents exactly one year of life lived in perfect health. If an intervention extends a patient's life by one year but leaves them in a state of health valued at 0.5—perhaps due to severe pain or limited mobility—that intervention has delivered half of a QALY. Death is anchored at zero, and certain severe health states, such as being locked-in or experiencing intractable agony, can be assigned negative values, representing a state considered worse than death.[1][6]

To calculate these utility values, health economists rely on standardized questionnaires, the most common being the EQ-5D. This tool asks patients to rate their health across five dimensions: mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. The responses are then mapped to a tariff of values derived from surveys of the general public, who are asked to imagine and score those health states. This ensures that the valuation reflects societal preferences rather than just the subjective experience of the patient, though this methodology remains a point of intense academic debate.[2][6]

Once the QALYs are calculated, they are fed into the Incremental Cost-Effectiveness Ratio (ICER). This formula divides the difference in cost between a new treatment and the standard of care by the difference in QALYs produced by the two options. If a new cancer drug costs $100,000 more than the current chemotherapy but delivers two additional QALYs, the ICER is $50,000 per QALY. This ratio is the engine of health technology assessment, providing a standardized benchmark to compare a leukemia treatment against a diabetes intervention or a new surgical technique.[3]

Different countries apply different thresholds to determine whether an ICER represents good value for money. In the United Kingdom, the National Institute for Health and Care Excellence (NICE) generally considers an intervention cost-effective if it falls below £20,000 to £30,000 per QALY gained. Interventions above this threshold are routinely rejected for funding by the National Health Service, forcing pharmaceutical companies to either lower their prices or abandon the market.[1]

In the United States, where there is no single national health system with a fixed budget, the thresholds are higher and less rigidly enforced. The Institute for Clinical and Economic Review (ICER), an independent watchdog, typically uses a benchmark of $100,000 to $150,000 per QALY. While federal programs like Medicare are legally prohibited from using cost-per-QALY thresholds to deny coverage, agencies like the Veterans Affairs Health Economics Resource Center (HERC) utilize cost-effectiveness analysis for internal planning and resource allocation.[3][7]

Despite its widespread adoption, the QALY faces significant methodological and ethical challenges. Patient advocacy groups argue that the metric inherently discriminates against the elderly and the disabled. Because a person with a chronic illness starts at a lower baseline utility—say, 0.6 instead of 1.0—a life-saving treatment that extends their life by one year will only generate 0.6 QALYs, compared to a full 1.0 QALY for a healthy person. This mathematical reality means treatments for the disabled appear less cost-effective, potentially deprioritizing their care in a rationed system.[6][7]

To address these equity concerns, health economists have developed alternative metrics. The Equal Value of Life Years Gained (evLYG) metric, increasingly used alongside the QALY, measures any extension of life equally, regardless of the patient's underlying quality of life. If a drug extends the life of a patient with multiple sclerosis by one year, it generates one evLYG, exactly as it would for a healthy individual. This hybrid approach allows policymakers to account for survival benefits without penalizing patients for pre-existing disabilities.[7]

Agencies are also refining how they account for the severity of the underlying disease. In 2022, NICE introduced a severity shortfall modifier, detailed in Technical Support Document 23 from the University of Sheffield. This mechanism gives extra weight to QALYs gained by treating conditions that cause a massive loss of future health, such as aggressive childhood cancers. By mathematically boosting the value of these interventions, the system attempts to align the rigid ICER formula with the public's intuitive desire to prioritize the sickest patients.[5]

Beyond ethical concerns, the fundamental mathematics of the QALY have been challenged. A 2023 analysis published in the Journal of Health Economics and Outcomes Research argued that utility values derived from questionnaires are ordinal data—meaning they represent a ranking of preferences—rather than cardinal data with equal intervals. Multiplying ordinal utility scores by time, the authors argue, violates basic mathematical principles, rendering the resulting QALY calculations structurally flawed and potentially misleading for policy decisions. Because this analysis relies entirely on technical methodological guidelines and mathematical critiques, the cited literature does not contain direct conversational quotations from individual researchers.[4][8]

Despite these flaws, health economists argue that abandoning the QALY would not eliminate rationing; it would simply drive it underground. Without a transparent, quantifiable metric, resource allocation would likely revert to political lobbying, emotional appeals, and the implicit rationing of the free market, where care is distributed based on the ability to pay rather than the clinical benefit delivered. The QALY, for all its imperfections, forces a health system to state exactly what it values and precisely how much it is willing to pay for it.[2][6]

The future of cost-effectiveness analysis lies in broadening the definition of value. Researchers are increasingly incorporating spillover effects—such as the impact of a treatment on unpaid caregivers' quality of life, or the broader economic benefits of returning a patient to the workforce. As these models become more sophisticated, the QALY will likely evolve from a blunt instrument of cost containment into a more nuanced reflection of how medical innovation impacts the entirety of human life.[1][3]